Mankind Pharma Ltd's Q3FY25 Quarter Results
- 24 Jan 2025
Result Summary
- Mankind Pharma Ltd reported a 3.8% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 23.5%.
- Its expenses for the quarter were up by 20.3% QoQ and 32.7% YoY.
- The net profit decreased 41.6% QoQ and decreased 16.4% YoY.
- The earnings per share (EPS) of Mankind Pharma Ltd stood at 9.4 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 3307.32 | 3185.94 | 2677.09 | 3.8% | 23.5% |
Total Expenses | 2813.43 | 2339.19 | 2119.37 | 20.3% | 32.7% |
Profit Before Tax | 493.89 | 846.75 | 557.73 | -41.7% | -11.4% |
Tax | 112.81 | 190.44 | 102.52 | -40.8% | 10.0% |
Profit After Tax | 384.52 | 658.88 | 459.81 | -41.6% | -16.4% |
Earnings Per Share | 9.40 | 16.30 | 11.30 | -42.3% | -16.8% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Mankind Pharma Ltd is a prominent player in the pharmaceutical industry, primarily engaged in the development, manufacturing, and marketing of a diverse range of pharmaceutical products. The company is known for its extensive portfolio that includes prescription generics, over-the-counter (OTC) products, and active pharmaceutical ingredients (APIs). Mankind Pharma has established a significant presence in both domestic and international markets, driven by its commitment to providing affordable healthcare solutions. Recent developments regarding the company are not available in the provided data, so any strategic moves or changes in market positioning are not discussed in this report.
Revenue
In the third quarter of the fiscal year 2025 (Q3FY25), Mankind Pharma Ltd reported a total income of ₹3307.32 crores. This marks an increase of 3.8% from the previous quarter, where the total income was ₹3185.94 crores in Q2FY25. Year-over-year, the company experienced a significant growth of 23.5% compared to ₹2677.09 crores in Q3FY24. This upward trend in revenue indicates a robust performance in the top line, reflecting the company's ability to generate higher sales over the comparative periods. The revenue growth can be attributed to its diverse product offerings and possible market expansion, although specific contributing factors are not detailed in the data provided.
Profitability
The profitability of Mankind Pharma Ltd shows mixed trends for the quarter under review. The company reported a profit before tax (PBT) of ₹493.89 crores in Q3FY25, which is a decrease of 41.7% from ₹846.75 crores in Q2FY25. Compared to the previous year, the PBT also declined by 11.4% from ₹557.73 crores in Q3FY24. The profit after tax (PAT) followed a similar trend, amounting to ₹384.52 crores, down by 41.6% from the preceding quarter and by 16.4% from the same quarter last year. The earnings per share (EPS) also witnessed a decline to ₹9.40 from ₹16.30 in the previous quarter and ₹11.30 in Q3FY24, indicating a reduction in profitability per share for shareholders. The reasons behind these declines are not specified in the provided data.
Operating Metrics
The total expenses for Mankind Pharma Ltd in Q3FY25 were ₹2813.43 crores, which represents a substantial increase of 20.3% from ₹2339.19 crores in Q2FY25, and a 32.7% rise from ₹2119.37 crores in Q3FY24. This increase in expenses could be indicative of higher operating costs or investments in business operations during the quarter. The tax expense for the quarter stood at ₹112.81 crores, showing a decrease of 40.8% from the previous quarter's ₹190.44 crores, but a 10% increase from ₹102.52 crores in the same quarter the previous year. These metrics highlight the company's operational cost dynamics and tax outlay, although specific drivers behind these changes are not discussed in the provided data. The provided information does not include additional financial ratios or metrics such as the P/E ratio, debt-to-equity ratio, or current ratio, which limits further analysis of the company's financial health.
